Deerfield Management Company L.P. Series C Increases Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Deerfield Management Company L.P. Series C increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 11.0% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 5,138 shares of the specialty pharmaceutical company’s stock after purchasing an additional 511 shares during the quarter. Deerfield Management Company L.P. Series C’s holdings in ANI Pharmaceuticals were worth $327,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Innealta Capital LLC acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $65,000. Ridgewood Investments LLC purchased a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $85,000. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals during the first quarter worth approximately $106,000. ADAR1 Capital Management LLC purchased a new position in ANI Pharmaceuticals during the fourth quarter worth approximately $132,000. Finally, Clear Street Markets LLC acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $140,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ANI Pharmaceuticals

In related news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the sale, the senior vice president now directly owns 193,226 shares of the company’s stock, valued at approximately $12,258,257.44. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $63.44, for a total value of $1,268,800.00. Following the completion of the transaction, the senior vice president now owns 193,226 shares of the company’s stock, valued at $12,258,257.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Muthusamy Shanmugam sold 14,257 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total value of $900,472.12. Following the sale, the chief operating officer now owns 635,363 shares of the company’s stock, valued at approximately $40,129,527.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,007 shares of company stock valued at $2,911,790. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Trading Up 0.8 %

NASDAQ:ANIP opened at $58.78 on Friday. The business’s 50-day moving average is $60.64 and its two-hundred day moving average is $63.44. The firm has a market capitalization of $1.23 billion, a PE ratio of 36.74 and a beta of 0.71. ANI Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.95 by $0.07. The firm had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. ANI Pharmaceuticals’s revenue for the quarter was up 18.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.06 EPS. Research analysts predict that ANI Pharmaceuticals, Inc. will post 3.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ANIP has been the subject of a number of research analyst reports. Raymond James upped their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Finally, Truist Financial reissued a “hold” rating and set a $60.00 target price (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.80.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.